Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: Implications for β-blocker selection

Clinical Science

Volumn 105, Issue 4, 2003, Pages 507-512

  Chin, Bernard S P ^a   Gibbs, Christopher R ^a   Blann, Andrew D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Bisoprolol; Carvedilol; Fibrinogen; Heart failure; Lipid hydroperoxide; Soluble P selectin; Von Willebrand factor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; FIBRINOGEN; LIPID HYDROPEROXIDE; LISINOPRIL; LOSARTAN; OXIDIZING AGENT; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CELL DAMAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DRUG CHOICE; DRUG EFFECT; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; MAXIMUM PERMISSIBLE DOSE; OUTPATIENT; OXIDATIVE STRESS; PRIORITY JOURNAL; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BISOPROLOL; CARBAZOLES; FEMALE; FIBRINOGEN; HEART FAILURE, CONGESTIVE; HUMANS; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDATIVE STRESS; P-SELECTIN; PROPANOLAMINES; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE; VASODILATOR AGENTS; VON WILLEBRAND FACTOR;

EID: 0141923086     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20030172     Document Type: Article

References (42)

1. Bristow, M. R. (1993) Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with β-blocking agents. Am. J. Cardiol. 71, 12C-22C
2. Curtiss, C., Conn, J. N., Vrobel, T. and Franciosca, J. A. (1978) Role of renin-angiotensin system in systemic vasoconstriction of chronic congestive heart failure. Circulation 58, 763-770
3. Francis, G. S., Benedict, C., Johnstone, D. E. et al. for the SOLVD Investigators. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 82, 1724-1729
4. Levine, T. B., Francis, G. S., Goldsmith, S. R., Simon, A. and Cohn, J. N. (1982) Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities. Am. J. Cardiol. 49, 1659-1666
5. Swedberg, K., Eneroth, P., Kjelkshus, J. and Wilhemsen, L. for the CONSENSUS Trial Study Group (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82, 1730-1736
6. Paolisso, G., Gambardella, A., Marrazzo, G. et al. (1992) Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am. Heart. J. 123, 103-110
7. Doughty, R. N., Rodgers, A., Sharpe, N. and MacMahon, S. (1997) Effects of β-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur. Heart J. 18, 560-565
8. Brown, N. J. and Vaughan, D. E. (1998) Angiotensin-converting enzyme inhibitors. Circulation 97, 1411-1420
9. Flather, M. D., Yusuf, S., Kober, L. et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575-1581
10. Keith, M., Geranmayegan, A., Sole, M. J. et al. (1998) Increased oxidative stress in patients with congestive heart failure. J. Am. Coll. Cardiol. 31, 1352-1356
11. Weir, R. R. and Dzau, V. J. (1999) The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am. J. Hypertens. 12, 205S-213S
12. Kaul, N., Siveski-iliskovic, N., Hill, M., Slezak, J. and Singal, P. K. (1993) Free radicals and the heart. J. Pharmacol. Toxical. Methods. 30, 55-67
13. Varin, R., Mulder, P., Tamion, F. et al. (2000) Improvement of endothelial function by chronic angiotensin-converting enzyme inhibiton in heart failure: role of nitric oxide, prostanoids, oxidant stress and bradykinin. Circulation 102, 351-356
14. Gibbs, C. R., Blann, A. D., Watson, R. D. and Lip, G. Y. H. (2001) Abnormalities of hemorheological, endothelial and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and β-blocker therapy. Circulation 103, 1746-1751
15. Feuerstein, G. Z., Yue, T. L., Cheng, H. Y. and Ruffolo, Jr, R. R. (1993) Myocardial protection by the novel vasodilating β-blocker, carvedilol: potential relevance of anti-oxidant activity. J. Hypertens. (Suppl) 11, S41-S48
16. Yue, T. L., McKenna, P. J., Gu, J. L., Cheng, H. Y., Ruffolo, Jr, R. and Feuerstein, G. Z. (1994) Carvedilol, a new vasodilating β adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc. Res. 28, 400-406
17. Ruffolo, Jr, R. R. and Feuerstein, G. Z. (1997) Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease and congestive heart failure. Cardiovasc. Drugs Ther. 11 (Suppl 1), 247-256
18. Feuerstein, G., Yue, T. L. and Ruffolo, R. R. (1998) Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals in apoptosis by carvedilol. Prog. Cardiovasc. Dis. 41 (Suppl 1), 17-24
19. CIBIS-II Investigators and Committees. (1999) The cardiac insufficiency study II (CIBIS-II): a randomised trial. Lancet 353, 9-13
20. Krum H. (1999) β-Blockers in heart failure. The 'new wave' of clinical trials. Drugs 58, 203-210
21. Nourooz-Zaden, J. and Tajaddini-Sarmadi, J. (1994) Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xyenol orange assay in conjunction with triphenylphosphine. Ann. Biochem. 220, 403-409
22. Altman, D. G. (1991) Practical statistics for medical research. Chapman & Hall, London
23. Sanderson, J. E., Chan, S. K. W., Yu, C. M. et al. (1998) β-Blockers in heart failure: a comparison of a vasodilating β-blocker with metoprolol. Heart 79, 86-92
24. Packer, M., Bristow, M. R., Cohn, J. N. et al. (1996) The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349-1355
25. Hjalmarson, A., Goldstein, S., Fagerberg, B. et al. (2000) Effects of controlled release metoprolol on total mortality, hospitalisations, and well being in patients with heart failure. The metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HP). JAMA, J. Am. Med. Assoc. 283, 1295-1302
26. Metra, M., Giubbini, R., Nodari, S., Boldi, E. and Modena, M. G. (2000) Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102, 546-551
27. Maack, C., Elter, T, Nickenig, G. et al. (2001) Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J. Am. Coll. Cardiol. 38, 939-946
28. Maxwell, S. R. and Lip, G. Y. H. (1997) Free radicals and antioxidants in cardiovascular disease. Br. J. Clin. Pharmacol. 44, 307-317
29. Blann, A. D., Maxwell, S. R. J., Burrows, G. and Miller, J. P. (1995) Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis 116, 191-198
30. Tse, W. Y., Maxwell, S. R. J., Blann, A. et al. (1994) Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial cell damage. J. Human Hypertens. 8, 843-849
31. Blann, A. D. and Lip, G. Y. H. (1998) The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coag. Fibrinolys. 9, 297-306
32. Hoeschen, R. J. (1997) Oxidative stress and cardiovascular disease. Can. J. Cardiol. 13, 1021-1025
33. Zalba, G., Beaumont, J., Sane Jose, G., Fortuno, A., Fortuno, M. A. and Diez, J. (2000) Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J. Physiol. Biochem. 56, 57-64
34. Kukin, M. L., Kalman, J., Charney, R. H. et al. (1999) Prospective randomised comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99, 2645-2651
35. Mansuy, P., Mougenot, N., Ramirez-Gil, J. F. et al. (2000) Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. J. Cardiovasc. Pharmacol. 35, 806-813
36. Anderson, R., Ramafi, G. and Theron, A. J. (1996) Membrane stabilising, anti-oxidative interactions of propanolol and dexpropranolol with neutrophils. Biochem. Pharmacol. 52, 341-349
37. Beanlands, R. S. B., Nahmias, C., Gordon, E. et al. (2000) The effects of β-1 blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction. Circulation 102, 2070-2081
38. Katz, A. (1986) Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73, 184-190
39. Singal, B. K., Beamish, R. E. and Dhalla, N. S. (1983) Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv. Exp. Med. Biol. 161, 391-401
40. Mueller, H. and Ayres, S. (1977) The role of propanolol in the treatment of acute myocardial infarction. Prog. Cardiovasc. Dis. 19, 405-412
41. Neely, J. and Morgan, H. (1974) Relationship between carbohydrate and lipid metabolism and energy balance of the heart. Rev. Physiol. 36, 413-459
42. Eichhorn, E. J., Bedotto, J. B., Malloy, C. R. et al. (1990) Effect of ν-adrenergic blockade on myocardial function and energetics in congestive heart failure. Circulation 82, 473-483